Bruker
Vernalis building
Vernalis building
CUSTOMER INSIGHT

NMR Spectroscopy: Fundamental to the Success of Early-Stage Drug Discovery

Vernalis has more than 25 years of experience in fragment-based and structure-based drug discovery, helping identify and advance the most promising candidates through the therapeutic pipeline. With expertise in tackling challenging targets, the team combines advanced methodologies and biophysical insight to accelerate early-stage drug discovery.

Reducing risk and improving confidence in hit identification and lead optimization is critical for successful drug discovery. In this customer insight, Dr. Davis, Research Fellow and Director of Business Development at Vernalis, explains how robust fragment screening and NMR-based characterization help distinguish true binders from false positives, enabling more confident decisions and helping teams focus resources on the most promising candidates.

Customer Insight

NMR Spectroscopy: Fundamental to the Success of Early Stage Drug Discovery